16.01.2013 • NewsDSMRoyal DSMAmgen

DSM Announces License Agreement with Amgen

DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM, announced today that it has signed a non-exclusive license agreement with Amgen for access to DSM's proprietary XD high cell density process patents.

XD technology is a highly intensified cell culture process with typical titer achievement of 8-to-10 times higher compared to current standard biomanufacturing processes. For some products, titer improvements of up to 15 times have been achieved. It is widely applicable for multiple biological products including proteins, fusion proteins and antibodies, and has been successfully employed across the full spectrum of mammalian cell systems.

 

CHEManager Spotlight

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics
Creating Interfaces

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics

CHEManager Spotlight is an exclusive event tailored for practitioners and decision-makers in the chemical industry. This part of our event series delves into the latest trends and innovations in logistics to streamline your operations and drive efficiency.

Virtual Event

DIGITALIZATION IN THE CHEMICAL INDUSTRY

DIGITALIZATION IN THE CHEMICAL INDUSTRY

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.